1-2 of 2
Anna Barbui, MD
Close
Sort by
Journal Articles

High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.

Sergio Cortelazzo, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Marco Ladetto, MD, Manuela Zanni, MD, Paolo Corradini, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Antonino Mulè€, MD, Ignazio Majolino, MD, Atto Billio, MD, Angela Gueli, MD, Francesco Di Raimondo, MD, Annalisa Chiarenza, MD, Andrea Gallamini, MD, Andres Ferreri, MD, Giovanni Pizzolo, MD, Fabio Benedetti, MD, Giorgio La Nasa, MD, Pietro Leoni, MD, Guido Gini, MD, Livio Trentin, MD, Francesco Rodeghiero, MD, Roberto Marchioli, MD, Tiziano Barbui, MD, Anna Barbui, MD, Alessandro Rambaldi, MD
Journal: Blood
Blood (2009) 114 (22): 1220.
https://doi.org/10.1182/blood.V114.22.1220.1220
Published: 2009
Journal Articles

Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.

Corrado Tarella, MD, Roberto Passera, PhD, Michele Magni, MD, Andrea Rossi, MD, Fabio Benedetti, MD, Angela Gueli, Jr., MD, Caterina Patti, MD, Guido Parvis, MD, Fabio Ciceri, MD, Andrea Gallamini, MD, Sergio Cortelazzo, MD, Paolo Corradini, MD, Valerio Zoli, MD, Antonio Mule', MD, Roberto Crocchiolo, MD, Marco Bosa, MD, Anna Barbui, MD, Massimo Di Nicola, MD, Daniele Caracciolo, MD, Marco Sorio, MD, Alessandro M. Gianni, MD, Alessandro Rambaldi, MD
Journal: Blood
Blood (2009) 114 (22): 519.
https://doi.org/10.1182/blood.V114.22.519.519
Published: 2009